Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

493 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular Pathways of Breast Cancer in Systemic Sclerosis: Exploratory Immunohistochemical Analysis from the Sclero-Breast Study.
Isca C, Spinella A, Toss A, de Pinto M, Ficarra G, Fabbiani L, Iannone A, Magnani L, Lumetti F, Macripò P, Vacchi C, Gasparini E, Piana S, Cortesi L, Maiorana A, Salvarani C, Dominici M, Giuggioli D. Isca C, et al. Among authors: maiorana a. J Pers Med. 2022 Dec 3;12(12):2007. doi: 10.3390/jpm12122007. J Pers Med. 2022. PMID: 36556228 Free PMC article.
Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.
Guarneri V, Generali DG, Frassoldati A, Artioli F, Boni C, Cavanna L, Tagliafico E, Maiorana A, Bottini A, Cagossi K, Bisagni G, Piacentini F, Ficarra G, Bettelli S, Roncaglia E, Nuzzo S, Swaby R, Ellis C, Holford C, Conte P. Guarneri V, et al. Among authors: maiorana a. J Clin Oncol. 2014 Apr 1;32(10):1050-7. doi: 10.1200/JCO.2013.51.4737. Epub 2014 Mar 3. J Clin Oncol. 2014. PMID: 24590635 Free article. Clinical Trial.
Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
Guarneri V, Dieci MV, Frassoldati A, Maiorana A, Ficarra G, Bettelli S, Tagliafico E, Bicciato S, Generali DG, Cagossi K, Bisagni G, Sarti S, Musolino A, Ellis C, Crescenzo R, Conte P. Guarneri V, et al. Among authors: maiorana a. Oncologist. 2015 Sep;20(9):1001-10. doi: 10.1634/theoncologist.2015-0138. Epub 2015 Aug 5. Oncologist. 2015. PMID: 26245675 Free PMC article. Clinical Trial.
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients.
Omarini C, Bettelli S, Caprera C, Manfredini S, Caggia F, Guaitoli G, Moscetti L, Toss A, Cortesi L, Kaleci S, Maiorana A, Cascinu S, Conte PF, Piacentini F. Omarini C, et al. Among authors: maiorana a. Cancer Biol Ther. 2018;19(10):879-886. doi: 10.1080/15384047.2018.1480287. Epub 2018 Aug 1. Cancer Biol Ther. 2018. PMID: 30067438 Free PMC article.
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: clinical applications.
Toss A, Piacentini F, Cortesi L, Artuso L, Bernardis I, Parenti S, Tenedini E, Ficarra G, Maiorana A, Iannone A, Omarini C, Moscetti L, Cristofanilli M, Federico M, Tagliafico E. Toss A, et al. Among authors: maiorana a. Oncotarget. 2018 Aug 3;9(60):31606-31619. doi: 10.18632/oncotarget.25810. eCollection 2018 Aug 3. Oncotarget. 2018. PMID: 30167082 Free PMC article.
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status.
Omarini C, Bettelli S, Caprera C, Manfredini S, Barbolini M, Moscetti L, Isca C, Toss A, Barbieri E, Cortesi L, Kaleci S, Maiorana A, Tazzioli G, Cascinu S, Piacentini F. Omarini C, et al. Among authors: maiorana a. J Cancer Res Clin Oncol. 2019 Apr;145(4):821-828. doi: 10.1007/s00432-018-02833-8. Epub 2019 Jan 2. J Cancer Res Clin Oncol. 2019. PMID: 30603906
493 results